secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2026-08-12T20:10:20+00:00
Accession:  0001193125-26-346857
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atara Q2 net loss $4.8M; FDA meeting backs tab-cel BLA resubmission
-------------------------------------------------------------------

- Q2 2026 net loss of $4.8M ($0.32/share) vs net income of $2.4M in Q2 2025.
- Total revenues $0.6M vs $17.6M YoY, down $17.0M on deferred revenue acceleration.
- Cash and short-term investments $9.9M at June 30, 2026; operating expenses down 87% YoY.
- Cash runway into mid-2027; productive Type A FDA meeting supports tab-cel BLA resubmission.
- Eligible for $31M milestone on FDA approval plus tiered royalties on EBVALLO sales.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000119312526346857/0001193125-26-346857-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000119312526346857/atra-20260812.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-346857

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer